Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
LXE
Lexeo Therapeutics
LXEO · NASDAQ · Biological Products, (No Diagnostic Substances)
Lexeo Therapeutics (LXEO) · oqro.io/stocks/LXEO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Lexeo Therapeutics insider trading
Have Lexeo Therapeutics insiders bought shares recently?
No open-market purchase by an insider of Lexeo Therapeutics was filed in the last 90 days. The latest on record was on Nov 26, 2024.
How often do Lexeo Therapeutics insiders buy and sell shares?
Since 2023, Lexeo Therapeutics insiders reported 4 open-market purchases and 28 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2024.
Who is selling Lexeo Therapeutics stock?
In the last 90 days, 3 insiders of Lexeo Therapeutics (LXEO) reported 3 open-market sales worth $18K in total on SEC Form 4. The largest seller by value was Richard Nolan Townsend, with $11K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade LXEO?
No trade in Lexeo Therapeutics (LXEO) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−66.8% (−$5.95) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $8.91 on Nov 20, 2025 to $2.96 on Nov 20, 2026 (−66.8%). Disclosed in this range: 0 insider trades, 3 pre-arranged insider sales, 0 Congress trades, and 12 13F position changes for 3 quarters ending in it.
$0$6$8$10$12$2.96
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 3 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in New York, Ny.
Last 12 months
−66.8%
S&P 500 +5.7% over the same dates
Market value
$243M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 17M shares sold short (20.8% of shares outstanding), −2.9% vs the previous count, 12.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
—
Free cash flow, last 12 months
−$87.7M
This quarter −$28.9M, a year earlier −$29.8M
Net debt
—
Debt —, cash $90.2M, at Sep 30, 2026
Net income, last 12 months
−$105M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 16, 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Risk factors in the annual report
Latest annual report filed Mar 30, 2026, compared with the one filed Mar 24, 2025. Read the filing
No longer listed (1 heading from the year before)
We cannot be certain that any of our or licensed pending patent applications or our future owned or licensed patent applications will result in issued patent claims covering such aspects of our product candidates.
Legal proceedings (Item 3)
From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. On October 12, 2023, Rocket filed a lawsuit in the U.S. District Court for the Southern District of New York against Lexeo and two former employees claiming, among other things, misappropriation of confidential information and trade secrets.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Lexeo Therapeutics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 3 open-market sales (about $18K, in 3 filings, by 3 people). One Form 4 can list many transactions. In the 12 months before that, they filed 1 open-market purchase (about $105K, in 1 filing) and 14 open-market sales (about $99K, in 14 filings). (Lexeo Therapeutics on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 10 new or larger positions and 2 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter. Paradigm BioCapital Advisors LP cut its LXEO stake below 5% (0%) (filed Nov 16, 2026).
Contracts, lobbying and filings. ClinicalTrials.gov shows 2 studys sponsored by the company updated in the period; the latest, "Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy" (Phase 2, status recruiting), was updated on Sep 2, 2026, with primary completion listed for 2032-06. FINRA short interest for LXEO on the settlement date of Oct 30, 2026 was 17,037,063 shares (-2.94% on the previous report), about 12.73 days of average volume.
Company reports, price and press. Lexeo Therapeutics filed a Form 8-K on Sep 29, 2026 (Items 2.01, 3.02) that OQRO classes as: completed buying or selling a business or assets, and sold new shares without registering them. The company's own opening sentence of that report reads: "Completion of Acquisition or Disposal of Assets."
Who holds it. 142 funds reported a stake in Lexeo Therapeutics in their 13F for Q2 2026. The largest by value: MONTANOVA CAPITAL, LLC (7.1% of the value reported), Affinity Asset Advisors, LLC (6.5% of the value reported), BlackRock, Inc. (6.4% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Lexeo Therapeutics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 3 open-market sales (about $18K, in 3 filings, by 3 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 1 open-market purchase (about $105K, in 1 filing) and 14 open-market sales (about $99K, in 14 filings).
The largest sale: Richard Nolan Townsend, Chief Executive Officer, about $11K, filed Nov 18, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 10 new or larger positions and 2 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Paradigm BioCapital Advisors LP cut its LXEO stake below 5% (0%) (filed Nov 16, 2026).
OrbiMed Advisors LLC cut its LXEO stake below 5% (3.9%) (filed Nov 16, 2026).
Contracts, lobbying and filings
ClinicalTrials.gov shows 2 studys sponsored by the company updated in the period; the latest, "Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy" (Phase 2, status recruiting), was updated on Sep 2, 2026, with primary completion listed for 2032-06.
FINRA short interest for LXEO on the settlement date of Oct 30, 2026 was 17,037,063 shares (-2.94% on the previous report), about 12.73 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Montanova Capital, LLC (increased, 5,134,200 shares); Frazier Life Sciences Management, L.P. (increased, 400,000 shares); the largest that shrank: E Fund Management Co., Ltd. (sold out); Bleakley Financial Group, LLC (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Lexeo Therapeutics filed a Form 8-K on Sep 29, 2026 (Items 2.01, 3.02) that OQRO classes as: completed buying or selling a business or assets, and sold new shares without registering them.
The company's own opening sentence of that report reads: "Completion of Acquisition or Disposal of Assets."
Lexeo Therapeutics filed a Form 8-K on Apr 30, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On April 28, 2026 (the ' Appointment Date '), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the ' Board ') of Lexeo Therapeutics, Inc. (the ' Company ')."
Lexeo Therapeutics filed a Form 8-K on Feb 5, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On January 30, 2026, Lexeo Therapeutics, Inc. (the 'Company') entered into a Transition and Consulting Agreement (the 'Transition Agreement') with Dr. Adler, effective February 1, 2026, pursuant to which Dr. Adler stepped down fr..."
Press coverage listed by Finnhub: "Lexeo Therapeutics Q3 Earnings Call Highlights" (Yahoo, Nov 16, 2026).
Press coverage listed by Finnhub: "Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study" (Benzinga, Nov 16, 2026).
Press coverage listed by Finnhub: "Lexeo Therapeutics shares surge 25% on interim data for LX2020 gene therapy" (Yahoo, Nov 16, 2026).
LXEO closed at $2.95 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $2.76 to $2.95, a change of +6.9%.
Who holds it
142 funds reported a stake in Lexeo Therapeutics in their 13F for Q2 2026. The largest by value: MONTANOVA CAPITAL, LLC (7.1% of the value reported), Affinity Asset Advisors, LLC (6.5% of the value reported), BlackRock, Inc. (6.4% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Insiders of Lexeo Therapeutics reported 4 open-market purchases and 28 sales since 2023; purchases in 2 different years, most recently 2024.
Year
Bought
Sold
2026
—
$18K3×3 trades
2025
—
$78K13×13 trades
2024
$105K1×1 trade
$1.27M12×12 trades
2023
$12.5M3×3 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Late-stage clinical trials
0 active phase 3 trials and 3 active phase 2 trials led by this company, mostly in friedreich ataxia, arrhythmogenic cardiomyopathy. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
From “Overview”, in the company's words
We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including FA cardiomyopathy, plakophilin-2, or PKP2, arrhythmogenic cardiomyopathy, or ACM, and other devastating diseases with high unmet need.
What the section covers (32 headings)
Overview
LX2006 for the treatment of FA cardiomyopathy
Interim Clinical Data Updates
Regulatory Alignment
LX2020 for the treatment of arrhythmogenic cardiomyopathy
Current and Future Capital Requirements
Components of our results of operations
Revenue
Operating expenses
Research and development
General and administrative
Gain on long-term investment
Other income (expense), net
Interest expense
And 18 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Off-exchange trading: 42.7% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (19.5% on ATS, 23.2% with other brokers), close to its 26-week average of 42.1%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: INTELLIGENT CROSS LLC (13.1%), UBS ATS (11.7%), SIGMA X2 (8.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Last 30 days
Written by software from the filings listed below · Nov 21, 2026
Insiders. In the 30 days to Nov 21, 2026, insiders of Lexeo Therapeutics filed 0 open-market purchases and 3 open-market sales (about $18K, in 3 filings, by 3 people). One Form 4 can list many transactions. In the 30 days before that, they filed 0 open-market purchases and 0 open-market sales. (Lexeo Therapeutics on OQRO)
Funds and stakes. Paradigm BioCapital Advisors LP cut its LXEO stake below 5% (0%) (filed Nov 16, 2026). OrbiMed Advisors LLC cut its LXEO stake below 5% (3.9%) (filed Nov 16, 2026).
Contracts, lobbying and filings. FINRA short interest for LXEO on the settlement date of Oct 30, 2026 was 17,037,063 shares (-2.94% on the previous report), about 12.73 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Montanova Capital, LLC (increased, 5,134,200 shares); Frazier Life Sciences Management, L.P. (increased, 400,000 shares); the largest that shrank: E Fund Management Co., Ltd. (sold out); Bleakley Financial Group, LLC (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Lexeo Therapeutics filed a Form 8-K on Nov 16, 2026 (Items 2.02, 7.01, 8.01) that OQRO classes as: reported its results, and shared information with investors (and 1 more item). The press release filed with it is titled: "Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial…"
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 30 days to Nov 21, 2026, insiders of Lexeo Therapeutics filed 0 open-market purchases and 3 open-market sales (about $18K, in 3 filings, by 3 people). One Form 4 can list many transactions.
In the 30 days before that, they filed 0 open-market purchases and 0 open-market sales.
The largest sale: Richard Nolan Townsend, Chief Executive Officer, about $11K, filed Nov 18, 2026.
Funds and stakes
Paradigm BioCapital Advisors LP cut its LXEO stake below 5% (0%) (filed Nov 16, 2026).
OrbiMed Advisors LLC cut its LXEO stake below 5% (3.9%) (filed Nov 16, 2026).
Contracts, lobbying and filings
FINRA short interest for LXEO on the settlement date of Oct 30, 2026 was 17,037,063 shares (-2.94% on the previous report), about 12.73 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Montanova Capital, LLC (increased, 5,134,200 shares); Frazier Life Sciences Management, L.P. (increased, 400,000 shares); the largest that shrank: E Fund Management Co., Ltd. (sold out); Bleakley Financial Group, LLC (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Lexeo Therapeutics filed a Form 8-K on Nov 16, 2026 (Items 2.02, 7.01, 8.01) that OQRO classes as: reported its results, and shared information with investors (and 1 more item).
The press release filed with it is titled: "Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial…"
Its announcing sentence reads: "Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced positive interim data from the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (P..."
Press coverage listed by Finnhub: "Lexeo Therapeutics Q3 Earnings Call Highlights" (Yahoo, Nov 16, 2026).
Press coverage listed by Finnhub: "Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study" (Benzinga, Nov 16, 2026).
Press coverage listed by Finnhub: "Lexeo Therapeutics shares surge 25% on interim data for LX2020 gene therapy" (Yahoo, Nov 16, 2026).
LXEO closed at $2.96 on Nov 20, 2026, the last session on or before the end of the period.
From Oct 21, 2026 to Nov 20, 2026, the close moved from $3.00 to $2.96, a change of −1.3%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Since Nov 18, 2025, LXEO is down 67.8% and the index fund is up 4.5%: 72 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much LXEO moves
A usual day
±2.7%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
12.6%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−23.0%Jan 12, 2026
Largest one-day rise
+14.3%May 20, 2026
Deepest fall of the year
−75.3%From the close of Dec 22, 2025 to Oct 14, 2026.
Days of 5% or more
56Out of 252 sessions, in either direction.
Beta 1.8(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
On the public record for Lexeo Therapeutics over the 12 months to Nov 21, 2026: 2 clinical trials.